Medicenna Therapeutics is an immunotherapy company developing interleukin-2, interleukin-4 and interleukin-13 tunable cytokines, called Superkines. These Superkines can be developed either on their own as short or long-acting therapeutics or fused with cell killing proteins in order to generate Empowered Superkines that deliver potent toxins to cancer cells. Superkines can also be fused with proteins, antibodies and other Superkines in order to incorporate two synergistic therapeutic activities into one molecule, creating Bi-Functional SuperKine ImmunoTherapies referred by Medicenna as BiSKITs™. Co.'s Product Candidate, MDNA55, is used for the treatment of tumors of the brain in adults. The MDNA average annual return since 2017 is shown above.
The Average Annual Return on the MDNA average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MDNA average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MDNA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free MDNA Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
